Pioneering novel GPCR-directed therapeutics for metabolic & endocrine diseases

Confo is creating new medicines with its unique approach

The field of GPCR-modulating therapeutics is rapidly evolving

Confo Therapeutics is a clinical-stage company committed to identifying & accelerating novel medicines for metabolic & endocrine diseases.

With our proprietary technology, we develop both small molecules & antibody-based therapies creating new treatment opportunities for patients.

Learn more about us

How we do this

Creating novel GPCR-directed therapeutics

Our proprietary, cutting-edge technology targets & modulates GPCRs to discover small molecule & antibody-based therapeutics.

Our approach can target class A & B GPCRs in new ways to discover agonists, antagonists, inverse agonists and allosteric modulators.

Tour our technology

Our team of innovators is advancing our pipeline, inventing new paths forward for patients. We’re also partnering with pharma companies that share our ambition to deliver novel product candidates using our proprietary approach.

Advancing our pipeline

Our programs focus on small molecule and antibody-based therapeutics

Discovery
Lead optimization
IND-enabling studies
Phase 1
Phase 2
Development rights
Peripheral Pain
Target: AT2R
Approach: Antagonist
Peripheral Pain
Target: AT2R
Approach: Antagonist
Phase 1

700

mil.

By 2050, over 700 million people worldwide are estimated to suffer from neuropathic pain, highlighting the urgent need for innovative treatments and effective management strategies to improve quality of life.

7-10

%

Neuropathic pain affects an estimated 7-10% of the global population, highlighting its widespread impact and the need for effective treatment solutions.

Phase 1

700

mil.

By 2050, over 700 million people worldwide are estimated to suffer from neuropathic pain, highlighting the urgent need for innovative treatments and effective management strategies to improve quality of life.

7-10

%

Neuropathic pain affects an estimated 7-10% of the global population, highlighting its widespread impact and the need for effective treatment solutions.

Confo Therapeutics is developing CFTX-1554, a non-opioid treatment for neuropathic pain. It targets the angiotensin II type 2 receptor (AT2R), addressing prior challenges of off-target toxicity in pain management.

  • Id est pulvinar dolor viverra dolor, curabitur.
  • Etiam dignissim in platea eros tellus malesuada pharetra.
More about peripheral pain
Obesity
Target: GPR75
Approach: Antagonist
Obesity
Target: GPR75
Approach: Antagonist
Lead Optimization
Lead Optimization
Hyperinsulinemia
Target: SSTR5
Approach: Agonist
Hyperinsulinemia
Target: SSTR5
Approach: Agonist
Lead Optimization
Lead Optimization
Peripheral Pain
Target: SSTR4
Approach: Agonist
Peripheral Pain
Target: SSTR4
Approach: Agonist
Lead Optimization
Lead Optimization
Immune-Mediated & Fibrotic Diseases
Target: MC1R
Approach: Agonist
Immune-Mediated & Fibrotic Diseases
Target: MC1R
Approach: Agonist
Discovery
Discovery
Hypoparathyroidism
Target: PTHR1
Approach: Agonist
Hypoparathyroidism
Target: PTHR1
Approach: Agonist
Discovery
Discovery
Additional Programs
Approach: MultiGen Platform
Additional Programs
Approach: MultiGen Platform
Discovery
Discovery

Discover Our Cutting-Edge Programs

Explore our pipeline

Industry leaders trust Confo Therapeutics

We are catalyzing breakthroughs, together with our strategic partners.

We’re hiring!

Discover new opportunities. Discover new medicines.

We’re looking for talented people who challenge the status quo. Join our international team of experts and make an impact.

Join our team